Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee

Phase 1

Completed

Conditions: Pain

Interventions: Drug: PF-05089771

First Posted Date: 2012-02-09

Last Posted Date: 2012-12-12

Lead Sponsor: Pfizer

Target Recruit Count: 80

Registration Number: NCT01529671

Locations: 🇧🇪
Pfizer Investigational Site, Brussels, Belgium

Efficacy Of PF-05089771 In Treating Postoperative Dental Pain

Phase 2

Completed

Conditions: Postoperative Dental Pain

Interventions: Drug: Ibuprofen
Drug: PF-05089771
Other: Placebo

First Posted Date: 2012-02-08

Last Posted Date: 2018-06-01

Lead Sponsor: Pfizer

Target Recruit Count: 235

Registration Number: NCT01529346

Locations: 🇺🇸
Central Texas Oral Surgery Associates, Austin, Texas, United States
🇺🇸
Premier Research Group Limited, Austin, Texas, United States
🇺🇸
PPD Development, LP, Austin, Texas, United States

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Phase 4

Completed

Conditions: Well-differentiated Pancreatic Neuroendocrine Tumor

Interventions: Drug: sunitinib

First Posted Date: 2012-02-03

Last Posted Date: 2019-07-30

Lead Sponsor: Pfizer

Target Recruit Count: 106

Registration Number: NCT01525550

Locations: 🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
🇷🇴
Institutul Clinic Fundeni, Centrul de Gastroenterologie si Hepatologie, Bucuresti, Romania
🇮🇳
Tata Memorial Hospital, Mumbai, Maharashtra, India

and more 23 locations

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: MabThera
Biological: PF-05280586
Biological: Rituxan

First Posted Date: 2012-02-03

Last Posted Date: 2019-11-19

Lead Sponsor: Pfizer

Target Recruit Count: 220

Registration Number: NCT01526057

Locations: 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇨🇴
Mix Supplier S.A, Medellin, Antioquia, Colombia
🇨🇴
IPS Centro Integral de Reumatologia del Cairbe, CIRCARIBE S.A.S., Barranquilla, Atlantico, Colombia

and more 80 locations

A Study Of Three PF-05190457 Formulations In Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: PF-05190457

First Posted Date: 2012-02-01

Last Posted Date: 2012-02-01

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT01522807

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan)

Completed

Conditions: Streptococcus Pneumoniae
Pneumococcal Vaccine

Interventions: Biological: 7-valent vaccine injection

First Posted Date: 2012-01-31

Last Posted Date: 2016-01-20

Lead Sponsor: Pfizer

Target Recruit Count: 1143

Registration Number: NCT01521897

Locations: 🇯🇵
Yokoyama Children's Clinic, Kasuga, Fukuoka, Japan

Study Looking at Longitudinal Changes in Fatigue and Health Status in Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous Anti-TNF-α Therapy

Completed

Conditions: Rheumatoid Arthritis

Interventions: Other: SC anti-TNF

First Posted Date: 2012-01-31

Last Posted Date: 2015-02-19

Lead Sponsor: Pfizer

Target Recruit Count: 62

Registration Number: NCT01521884

Locations: 🇧🇪
UZ Gasthuisberg, Leuven, Belgium

A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: CP-690,550
Drug: CP-690, 550

First Posted Date: 2012-01-26

Last Posted Date: 2015-08-13

Lead Sponsor: Pfizer

Target Recruit Count: 95

Registration Number: NCT01519089

Locations: 🇯🇵
Tokyo Medical University Hospital, Shinjyuku-ku, Tokyo, Japan
🇯🇵
JR Sapporo hospital, Sapporo, Hokkaido, Japan
🇯🇵
Kobe University Hospital, Chuo-ku, Kobe, Hyogo, Japan

and more 13 locations

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: PF-04937319 100 mg
Drug: Placebo
Drug: PF-04937319 10 mg
Drug: PF-04937319 50 mg
Drug: Glimepiride

First Posted Date: 2012-01-25

Last Posted Date: 2017-01-31

Lead Sponsor: Pfizer

Target Recruit Count: 304

Registration Number: NCT01517373

Locations: 🇧🇬
MBAL Yulia Vrevska - Byala, Otdelenie po vatreshni bolesti, Byala, Bulgaria
🇧🇬
DKTs Akta Medika, Kabinet po endokrinologia, Sevlievo, Bulgaria
🇨🇦
Ocean West Research Clinic Inc., Surrey, British Columbia, Canada

and more 50 locations

A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2012-01-20

Last Posted Date: 2012-03-12

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT01513928

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy